PT Sinergi Multi Lestarindo Tb (SMLE) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of PT Sinergi Multi Lestarindo Tb stock IDR 103, price IDR 258, upside -60.3%, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
34‑month range 50.00 IDR – 426.00 IDR · fair‑value band 85.54 IDR – 131.78 IDR · the 258.00 IDR price screens above the 102.50 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow PT Sinergi Multi Lestarindo Tb in your weekly email
Every Wednesday you see whether PT Sinergi Multi Lestarindo Tb is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Sinergi Multi Lestarindo Tbk engages in the trading of specialty chemicals for food and beverage, personal care raw materials, and industrial chemical raw materials in Indonesia.
Show moreShow less
The company's products are used in various applications, including seasonings and condiments, processed meat and seafood, beverages and dairy, sauce and mayonnaise, bakery and snack, confectionery and chocolate, nutraceutical, coating, and animal nutrition; face, body, and hair care products, as well as baby products and cosmetics; and PVC products, plastic resins, fillers and additives, and pigments.
PT Sinergi Multi Lestarindo Tbk was founded in 2013 and is headquartered in Jakarta Barat, Indonesia. PT Sinergi Multi Lestarindo Tbk operates as a subsidiary of PT Sinergi Asia Corporindo.
Stock analysis
PT Sinergi Multi Lestarindo Tb (SMLE) currently trades at 258.00 IDR, while our model-based Fair Value estimate is 102.50 IDR, 60.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 74.67 IDR per share, and 0 of the 22 models we run sit above the 258.00 IDR price.
Bear case: the Asset-Based group reads lowest at 24.08 IDR, and 22 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: 85.54 IDR (bear) to 131.78 IDR (bull), the price of 258.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PT Sinergi Multi Lestarindo Tb reported revenue of 219B IDR in FY2025 versus 127B IDR in FY2021, a compound +14.7%/yr. Reported net income was 256M IDR in FY2025, compounding −52.4%/yr from FY2021.
Key figures
Market cap 601B IDR (≈ $33.0M) Micro · P/S ratio 2.84 · Net margin −3.2% · Return on equity −6.3% · Return on assets (EBIT) 10.1% · Operating margin 4.9% · Revenue (TTM) 206B IDR · Revenue growth (YoY) −4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 274% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −55% fair-value upside, at −60%, SMLE screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (1.83 IDR to 138.25 IDR). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear85.54 IDRFair Value 102.50 IDRBull131.78 IDR
Price 258.00 IDR · Upside -60.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 4%
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare PT Sinergi Multi Lestarindo Tb with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 723 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside−60.3% · Bottom 25%
Profitability
Return on assets0.1% · Bottom 25%
Net margin (12 months)−3.2% · Bottom 25%
Operating margin (12 months)4.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)−4.8% · Bottom 25%
Balance sheet
Debt / equity0.09× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/B5.60× · Priciest 25%
P/S (12 months)2.91× · Priciest 25%
EV/EBITDA69.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 65
PAST (return on equity)0· sector 26
HEALTH (low debt)96· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PT Sinergi Multi Lestarindo Tb Fair Value". https://www.fairvalue-calculator.com/stock/SMLE
Frequently asked questions
Is PT Sinergi Multi Lestarindo Tb (SMLE) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 102.50 IDR versus a price of 258.00 IDR, about −60% upside (overvalued).
What is the fair value of SMLE?
Our model-based fair value for PT Sinergi Multi Lestarindo Tb is 102.50 IDR (as of Oct 29, 2026), built from audited fundamentals. The current price: 258.00 IDR.
What is the quality score of SMLE?
PT Sinergi Multi Lestarindo Tb has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Sinergi Multi Lestarindo Tb (SMLE)?
Our model-based price target is the fair value of 102.50 IDR (as of Oct 29, 2026) from 22 valuation models. Cautious scenario 85.54 IDR, optimistic scenario 131.78 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Sinergi Multi Lestarindo Tb stock forecast for 2026?
Our models put fair value at 102.50 IDR, about −60% upside versus a price of 258.00 IDR (overvalued). Cautious scenario 85.54 IDR, optimistic scenario 131.78 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Sinergi Multi Lestarindo Tb (SMLE)?
PT Sinergi Multi Lestarindo Tb reported trailing-twelve-month revenue of about 206B IDR (latest available figure, as of Oct 29, 2026).
What growth is priced into PT Sinergi Multi Lestarindo Tb (SMLE)?
For today's price to be fair in a discounted-cash-flow model, PT Sinergi Multi Lestarindo Tb would have to grow free cash flow by more than 80 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.8 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of SMLE use?
Our models discount PT Sinergi Multi Lestarindo Tb at 11.2 %: a base by market capitalisation (nano), damped by beta 0.73, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PT Sinergi Multi Lestarindo Tb that is more than 80 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has PT Sinergi Multi Lestarindo Tb (SMLE) delivered so far?
Over the past 5 years revenue at PT Sinergi Multi Lestarindo Tb grew +18.8 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PT Sinergi Multi Lestarindo Tb (SMLE) growing?
The median revenue growth in the sector is +11.2 % a year. That is the yardstick for the growth priced into PT Sinergi Multi Lestarindo Tb (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PT Sinergi Multi Lestarindo Tb (SMLE)?
The free-cash-flow yield on the price is 0.19 %: that much free cash flow PT Sinergi Multi Lestarindo Tb produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PT Sinergi Multi Lestarindo Tb (SMLE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Sinergi Multi Lestarindo Tb it is 102.50 IDR per share (as of Oct 29, 2026), against a price of 258.00 IDR. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is PT Sinergi Multi Lestarindo Tb stock overvalued or undervalued in 2026?
As of Oct 29, 2026, SMLE trades above its calculated fair value: price 258.00 IDR, fair value 102.50 IDR, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMLE?
No. The price is what the market pays today (258.00 IDR); the fair value is what the company's own numbers justify (102.50 IDR). For PT Sinergi Multi Lestarindo Tb the two are 155.50 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Sinergi Multi Lestarindo Tb worth?
The market values PT Sinergi Multi Lestarindo Tb at about 601B IDR (market capitalisation, as of Oct 29, 2026). Per share that is 258.00 IDR; our models calculate a fair value of 102.50 IDR per share.
What do the bullish and bearish scenarios say about SMLE?
Our models span a range for PT Sinergi Multi Lestarindo Tb: cautious scenario 85.54 IDR, base 102.50 IDR, optimistic 131.78 IDR per share (as of Oct 29, 2026, price 258.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Sinergi Multi Lestarindo Tb (SMLE)?
Balance-sheet figures for PT Sinergi Multi Lestarindo Tb (as of Oct 29, 2026): return on equity −6.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is SMLE from its 52-week high?
PT Sinergi Multi Lestarindo Tb trades at 258.00 IDR, about 24% below its 52-week high of 340.00 IDR and 274% above the low of 69.00 IDR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 102.50 IDR is for.
Which stocks are comparable to PT Sinergi Multi Lestarindo Tb?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Givaudan SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Sinergi Multi Lestarindo Tb stock attractive at the current price?
The data as of Oct 29, 2026: price 258.00 IDR, calculated fair value 102.50 IDR (−60%), Quality Score 38/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SMLE calculated?
We run PT Sinergi Multi Lestarindo Tb through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 102.50 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. PT Sinergi Multi Lestarindo Tb itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Sinergi Multi Lestarindo Tb (SMLE)?
The closing price on Oct 28, 2026 was 258.00 IDR. Our model-based fair value is 102.50 IDR, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Sinergi Multi Lestarindo Tb right now?
The price sits above even our optimistic bull case (131.78 IDR). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of PT Sinergi Multi Lestarindo Tb
How large is the market capitalisation of PT Sinergi Multi Lestarindo Tb (SMLE)?
The market capitalisation of PT Sinergi Multi Lestarindo Tb is 601B IDR (≈ $33.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Sinergi Multi Lestarindo Tb (SMLE)?
The price-to-sales ratio of PT Sinergi Multi Lestarindo Tb is 2.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PT Sinergi Multi Lestarindo Tb (SMLE)?
The net margin of PT Sinergi Multi Lestarindo Tb is −3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Sinergi Multi Lestarindo Tb (SMLE)?
The return on equity (ROE) of PT Sinergi Multi Lestarindo Tb is −6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Sinergi Multi Lestarindo Tb (SMLE)?
On an EBIT basis the return on assets of PT Sinergi Multi Lestarindo Tb is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Sinergi Multi Lestarindo Tb (SMLE)?
The operating margin of PT Sinergi Multi Lestarindo Tb is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Sinergi Multi Lestarindo Tb (SMLE)?
Revenue at PT Sinergi Multi Lestarindo Tb is growing −4.8% versus a year earlier (3y avg +14.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Sinergi Multi Lestarindo Tb (SMLE)?
Earnings per share at PT Sinergi Multi Lestarindo Tb are growing +140% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PT Sinergi Multi Lestarindo Tb (SMLE) carry?
The net debt of PT Sinergi Multi Lestarindo Tb is 3.2B IDR (fiscal year 2025, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PT Sinergi Multi Lestarindo Tb in the live analysis
One click puts PT Sinergi Multi Lestarindo Tb on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 29, 2026